IQVIA delivered strong fourth quarter and full year 2025 results, with Q4 revenue growing 10.3% year-over-year to $4.34 billion and full year revenue reaching $16.31 billion, up 5.9%. Adjusted EPS grew 9.6% in Q4 to $3.42 and 7.1% for the full year to $11.92, driven by robust demand in R&D where net bookings increased 7% and backlog hit a record $32.7 billion. Management highlighted the successful integration of AI through partnerships with AWS and NVIDIA, positioning the company as a leader in 'healthcare-grade AI' while announcing a strategic restructuring into two segments (Commercial Solutions and R&D Solutions) for 2026. For the full year 2026, IQVIA guides for revenue of $17.16B-$17.36B and Adjusted EPS of $12.55-$12.85, reflecting confidence in continued growth despite macro headwinds.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $4.34 billion | +10.3% (Reported) |
| FY 2025 Revenue | $16.31 billion | +5.9% (Reported) |
| Q4 Adjusted EPS | $3.42 | +9.6% |
| FY 2025 Adjusted EPS | $11.92 | +7.1% |
| Q4 Adjusted EBITDA | $1.046 billion | +5.0% |
| FY 2025 Free Cash Flow | $2.51 billion | 99% of Adj. Net Income |
| R&D Backlog | $32.7 billion | +5.3% |
| Net Bookings (Q4) | $2.7 billion | +7% |
| Book-to-Bill | 1.18 | N/A |
AI as a Core Growth Driver: IQVIA is aggressively positioning itself as the premier partner for 'healthcare-grade AI' through strategic partnerships with AWS (preferred cloud provider) and NVIDIA (agentic AI). Management emphasized that their proprietary, de-identified data assets and deep domain expertise create a wide moat against generic AI models. They have deployed over 150 agents across 30 use cases, which they believe will drive productivity gains and new revenue streams rather than disrupt their existing business.
Organizational Restructuring: Effective 2026, IQVIA is simplifying its reporting structure into two primary segments: Commercial Solutions and R&D Solutions. This realignment moves the Contract Sales and Medical Solutions (CSMS) segment into Commercial Solutions and shifts real-world late-phase offerings into R&D Solutions. This change reflects client purchasing trends towards integrated solutions and aims to enhance collaboration without significantly altering overall growth rates.
M&A and Capability Expansion: The company continues to execute on tuck-in acquisitions to bolster specific capabilities. Notably, the acquisition of Cedar Gate expands their payer analytics footprint in the US (~$125M revenue, ~33% EBITDA margin). Other acquisitions like Next Oncology and a UK Phase I facility strengthen their clinical trial infrastructure, particularly in high-growth areas like oncology and early-phase research.
R&D Demand Recovery: There is a clear signal of recovery in the R&D environment. After a slow start to 2025 due to macro pressures and biotech funding constraints, the environment stabilized. Q4 saw net bookings grow 7% year-over-year to over $2.7 billion, RFP flow grow double digits, and the net book-to-bill ratio reach 1.18. This suggests a positive trajectory for the R&D segment into 2026.
AI Disruption Risk Perception: Despite management's strong defense, the intense analyst focus on AI disruption suggests the market remains skeptical about the long-term defensibility of the CRO model against advancing AI technologies. Investors are concerned that Pharma clients may utilize AI to bring work in-house or reduce reliance on external FSP (Functional Service Provider) seats, potentially pressuring future growth rates.
Margin Pressure from Pass-Throughs: Fourth quarter Adjusted EBITDA growth (5%) significantly lagged revenue growth (10.3%), primarily due to strong pass-through revenue and product mix. While management expects this dynamic to moderate in 2026, the discrepancy highlights the sensitivity of profitability to revenue mix and the potential for margin volatility if high-growth, lower-margin pass-through business continues to outpace core service growth.
Elevated Cancellations: Management noted that Q4 cancellations were 'slightly above the normal range' due to idiosyncratic trial futility issues. While the overall book-to-bill remained healthy at 1.18, the elevated cancellations introduce variability and could impact visibility if this trend persists or indicates client hesitation in specific therapeutic areas.
CFO Transition: The departure of long-time CFO Ron Bruehlman introduces an element of uncertainty during a period of strategic restructuring and complex AI integration. While he is moving to a senior advisory role, the loss of his financial stewardship is a notable change for investors to monitor.
Overall: Management, particularly CEO Ari Bousbib, displayed a highly confident yet notably defensive demeanor regarding the company's AI positioning. While celebrating strong financial metrics and operational execution, Bousbib spent considerable time in the Q&A aggressively refuting external concerns about AI disruption, emphasizing the proprietary nature of IQVIA's data assets. CFO Ron Bruehlman maintained a steady, factual tone during his financial presentation, marking a smooth transition before his retirement.
Confidence: HIGH - Management expressed strong conviction in their business model and growth trajectory, evidenced by solid guidance and aggressive rebuttals to AI skepticism. They cited specific metrics like record backlog and double-digit RFP growth to support their positive outlook.
$17.159 billion - $17.359 billion
$3.975 billion - $4.25 billion
$12.55 - $12.85
$4.15 billion - $4.50 billion
$2.77 - $2.80
Hedging & Uncertainty: Management utilized minimal hedging regarding financial performance but employed significant defensive language to address AI concerns. Ari Bousbib used phrases like 'I don't know where to start' and 'I beg your patience' to frame his rebuttal, shifting from standard corporate speak to a more assertive, educational tone. He used definitive, absolute language ('It's just not available,' 'No one has duplicated it') to describe their data moat, attempting to close the door on skepticism. In contrast, guidance language contained standard probabilistic hedges such as 'we expect' and 'approximately,' maintaining typical forward-looking caution.
Our proprietary data assets, which are not stoppable by horizontal AI models are more valuable than ever actually. - Ari Bousbib, Chairman and CEO
AI justification is a positive, has been a positive, will continue to be a positive for us. - Ari Bousbib, Chairman and CEO
We started on this AI journey a long time ago. - Ari Bousbib, Chairman and CEO
The biggest driver that gross margin is finally saw was very strong pass-through growth in the quarter. - Ronald Bruehlman, Executive Vice President and CFO
We do not see any change in demand dynamics. We only see opportunities for productivity improvements. - Ari Bousbib, Chairman and CEO
Analyst Sentiment: Analysts were highly focused on the potential for AI to disrupt IQVIA's business model, asking multiple questions about whether AI would reduce demand for FSP seats or enable clients to bring work in-house. There was also notable interest in the margin profile and strategic fit of the Cedar Gate acquisition.
Management Responses: CEO Ari Bousbib was assertive and detailed in his responses, attempting to educate analysts on the complexity of healthcare data and why IQVIA's proprietary assets are defensible against horizontal AI models. He expressed frustration with the market's focus on AI disruption, reiterating that it is an opportunity, not a threat.
AI Disruption vs. Opportunity: Management argued that AI requires proprietary data and domain expertise which IQVIA possesses, making them an enabler rather than a victim of the technology.
Cedar Gate Acquisition: Details were provided on the $125M revenue, 33% margin business, expanding payer analytics capabilities.
Margins and Pass-throughs: Management explained Q4 margin pressure was due to pass-through revenue mix and expects this to normalize in 2026.
R&D Demand Environment: Confirmed stabilization and improvement in biotech funding and RFP flow, supporting the 1.18 book-to-bill ratio.
IQVIA remains a core holding in the healthcare space, demonstrating resilience and growth acceleration in Q4 despite a challenging macro environment. The market's current fear regarding AI disruption appears to overlook the critical necessity of IQVIA's proprietary, compliant healthcare data assets and deep domain expertise, which serve as a formidable moat. Management's aggressive defense of their AI strategy, coupled with tangible results like record backlog ($32.7B) and strong free cash flow ($2.5B), supports a positive long-term view. The restructuring into two segments streamlines operations and aligns with client needs, while the AWS/NVIDIA partnerships position them to monetize AI efficiency. While margin pressure from pass-throughs is a near-term headwind, the robust guidance for 2026 (revenue growth ~5-6%, EPS growth ~5-8%) signals confidence in sustainable earnings growth.
Management noted that biotech funding has returned and the macro environment stabilized as 2025 progressed, leading to improved R&D demand and double-digit RFP flow growth.
Continued pressure from interest rates was cited as a headwind earlier in the year that slowed customer decision-making, though conditions have since improved.
AI is viewed as a productivity tool that will augment rather than replace human expertise in healthcare, driving efficiency in clinical trials and commercialization.